07:00 , Jun 13, 2016 |  BioCentury  |  Product Development

Small cell synergy

Investors and others watching data coming from the American Society of Clinical Oncology meeting were quick to pan overall survival data from a Phase I study of single-agent Rova-T rovalpituzumab tesirine in recurrent small cell...